Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023473 (
chronic myeloid leukemia
)
18,916
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Hfz5 is a potent cancer associated gene, encoding WNT receptor with the potential to activate beta-catenin - TCF signaling pathway. Here, human
Frizzled-5
(
FZD5
) gene and cDNAs were cloned and characterized.
FZD5
was almost identical to Hfz5, except for six amino-acid substitutions at codon 88, 262, 263, 345, 357, and 402. HF5S1 probe (nucleotide position 2036-2535 of
FZD5
cDNA) hybridized to 7.5- and 3.5-kb
FZD5
mRNAs, and HF5S2 probe (nucleotide position 5572-6194 of
FZD5
cDNA) hybridized only to 7.5-kb
FZD5
mRNA.
FZD5
cDNA was polyadenylated at the nucleotide position 6534, while several
FZD5
ESTs were polyadenylated at the nucleotide position 2561. The 7.5- and 3.5-kb
FZD5
mRNAs were transcribed probably due to alternative splicing.
FZD5
was highly expressed in fetal liver and adult pancreas, and moderately expressed in fetal lung, kidney and adult liver. Among human cancer cell lines,
FZD5
was highly expressed in K-562 cells derived from
chronic myelogenous leukemia
.
FZD5
gene, consisting of two exons, was mapped to human chromosome 2q33.3-q34 region, near the FZD7 gene and the FRA2I fragile site. These results suggest that
FZD5
up-regulation might play key roles in
chronic myelogenous leukemia
through activation of the WNT - beta-catenin - TCF signaling pathway.
...
PMID:Molecular cloning and characterization of human Frizzled-5 gene on chromosome 2q33.3-q34 region. 1140 29